Axinn Protects Client Endo Pharmaceuticals Inc.’s Approval for Generic Valcyte®
March 11, 2015
Axinn, on behalf of client Endo Pharmaceuticals Inc., successfully defended the U.S. Food and Drug Administration’s final approval of Endo’s generic Valcyte® by securing summary judgment in favor of Endo and FDA. Plaintiff Ranbaxy Laboratories, Ltd. had sought an order reversing FDA’s approval of Endo’s generic Valcyte® product after FDA recently decided to revoke tentative approval of Ranbaxy’s generic Valcyte® ANDA and determined that Ranbaxy had forfeited its generic marketing exclusivity rights. Judge Beryl Howell of the United Stated District Court for the District of Columbia determined that FDA had acted within its authority.
Related People
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
Axinn Associates at the Antitrust Spring Meeting: AI, Algorithms, and Information Exchange
Axinn Viewpoints
Axinn Associates at the Antitrust Spring Meeting: Perspectives on the DOJ Antitrust Division’s Whistleblower Rewards Program
Axinn Viewpoints
Axinn Associate Maryanne Magnier Appointed to Volunteer Legal Advocates Junior Board
Pro Bono
Axinn Associates at the Antitrust Spring Meeting: Trends in State and Private Enforcement
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Sector-Specific Enforcement Trends
Axinn Viewpoints
Antitrust
Conspiracy Theories Newsletter, 2026 Edition
Byline Articles
Antitrust
Axinn Partners John Harkrider and Craig Minerva Win 2026 Concurrences Antitrust Writing Award
Awards & Recognitions
Antitrust
Axinn Wins Firm of the Year – Americas at 2026 Global Competition Review Awards
Awards & Recognitions
Antitrust
